Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EP 217609

Known as: EP-217609, EP217609 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
SummaryEP217609 is a parenteral antithrombotic compound combining in one molecule an indirect anti-factor Xa inhibitor, a direct… Expand
  • figure 1
  • figure 3
  • figure 2
  • table 1
  • table 2
2016
2016
IntroductionEP217609 is a representative of a new class of synthetic parenteral anticoagulants with a dual mechanism of action… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 3
Review
2016
Review
2016
Thrombosis is a complex process involving multiple pathways. Currently, therapy relies on the combination of two or more… Expand
2015
2015
EP217609 is a new synthetic parenteral dual-action anticoagulant combining a direct thrombin inhibitor (α-NAPAP analog), an… Expand
Review
2015
Review
2015
RésuméObjectifL’héparine et la protamine constituent la stratégie d’anticoagulation de référence en chirurgie cardiaque sous… Expand
Review
2015
Review
2015
Heparin anticoagulation followed by protamine reversal is commonly used in cardiopulmonary bypass (CPB) cardiac procedures, but… Expand
2012
2012
EP217609 is a new dual-action parenteral anticoagulant that combines an indirect factor Xa inhibitor (fondaparinux analog) and a… Expand
  • table 1
  • table 2
  • table 3
Review
2011
Review
2011
The therapeutic armamentarium of parenteral anticoagulants available to clinicians is mainly composed by unfractionated heparin… Expand
  • figure 1
  • table 2
  • table 3
Review
2009
Review
2009
The elucidation of the structure of the antithrombin binding sequence in heparin has given a large impulse to the rational design… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1